.jpg) | |
| Discipline | Cell biology, immunology, stem cells |
|---|---|
| Language | English |
| Edited by | Edwin Horwitz |
| Publication details | |
Former name(s) | Cytokines, Cellular and Molecular Therapy; Cytokines and Molecular therapy |
| History | 1999-present |
| Publisher |
Elsevier on behalf of the
International Society for Cell & Gene Therapy |
| Frequency | 12/year |
| 5.414 (2020) | |
| Standard abbreviations | |
| ISO 4 | Cytotherapy |
| Indexing | |
| CODEN | CYTRF3 |
| ISSN |
1465-3249 (print) 1477-2566 (web) |
| LCCN | 00243205 |
| OCLC no. | 288963798 |
| Links | |
Cytotherapy is a peer-reviewed medical journal covering the areas of cell and gene therapy. The journal was established in 1999 and is published by Elsevier on behalf of the International Society for Cell & Gene Therapy (ISCT). Cytotherapy is edited by Editor-in-Chief Edwin Horwitz, Managing Editor Kenneth W. Witwer, Commissioning Editor Patrick Hanley, and Assistant Editor Rachel Burga.
Aims and Scope
The Journal publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. Cytotherapy publishes articles exploring the following topics:
- Development and/or characterization of novel gene therapies and cell and/or extracellular vesicle (EV)-based therapeutics.
- Design of novel therapeutic approaches employing cell/EV/gene products.
- Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
- Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.
- Role of stem/stromal cells and/or EVs in disease pathophysiology.
- Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.
- Important advances in cell/EV/gene-based product manufacturing and validation.
- Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.
Abstracting and indexing
This journal is abstracted and indexed in Science Citation Index Expanded, Current Contents/Clinical Medicine, Current Contents/ Life Sciences, BIOSIS Previews, and MEDLINE/ PubMed. According to the Journal Citation Reports, the journal has a 2020 impact factor of 5.414. [1]
References
- ^ "Journal Citation Reports". Clarivate Analytics. Retrieved 2021-07-07.
External links
 | This article about a molecular and cell biology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |
|
| |
| Discipline | Cell biology, immunology, stem cells |
|---|---|
| Language | English |
| Edited by | Edwin Horwitz |
| Publication details | |
Former name(s) | Cytokines, Cellular and Molecular Therapy; Cytokines and Molecular therapy |
| History | 1999-present |
| Publisher |
Elsevier on behalf of the
International Society for Cell & Gene Therapy |
| Frequency | 12/year |
| 5.414 (2020) | |
| Standard abbreviations | |
| ISO 4 | Cytotherapy |
| Indexing | |
| CODEN | CYTRF3 |
| ISSN |
1465-3249 (print) 1477-2566 (web) |
| LCCN | 00243205 |
| OCLC no. | 288963798 |
| Links | |
Cytotherapy is a peer-reviewed medical journal covering the areas of cell and gene therapy. The journal was established in 1999 and is published by Elsevier on behalf of the International Society for Cell & Gene Therapy (ISCT). Cytotherapy is edited by Editor-in-Chief Edwin Horwitz, Managing Editor Kenneth W. Witwer, Commissioning Editor Patrick Hanley, and Assistant Editor Rachel Burga.
Aims and Scope
The Journal publishes novel and innovative results from high quality scientific and clinical studies in the fields of cell and gene therapy. Cytotherapy publishes articles exploring the following topics:
- Development and/or characterization of novel gene therapies and cell and/or extracellular vesicle (EV)-based therapeutics.
- Design of novel therapeutic approaches employing cell/EV/gene products.
- Mode of action of cell/EV/gene therapies in relevant cell-based and pre-clinical models.
- Identification of novel biomarkers that predict the potency of cell/EV/gene therapies and/or stratify patients based on response rates.
- Role of stem/stromal cells and/or EVs in disease pathophysiology.
- Early and late phase clinical studies evaluating the safety and efficacy of cell/EV/gene therapies.
- Important advances in cell/EV/gene-based product manufacturing and validation.
- Global/regional regulatory practices that impact the authorized use and/or regulatory approval of cell/EV and gene therapies.
Abstracting and indexing
This journal is abstracted and indexed in Science Citation Index Expanded, Current Contents/Clinical Medicine, Current Contents/ Life Sciences, BIOSIS Previews, and MEDLINE/ PubMed. According to the Journal Citation Reports, the journal has a 2020 impact factor of 5.414. [1]
References
- ^ "Journal Citation Reports". Clarivate Analytics. Retrieved 2021-07-07.
External links
|
| This article about a molecular and cell biology journal is a stub. You can help Wikipedia by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |